An evaluation of the efficacy and safety of erdafitinib for the treatment of bladder cancer

Nauseef, Jones T.; Villamar, Dario Martin; Lebenthal, Justin; Vlachostergios, Panagiotis J.; Tagawa, Scott T.

doi:10.1080/14656566.2020.1736036

Cited by 8 publications

(4 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Erdafitnib (JNJ‐42756493), Pemigatinib (INCB054828), and Infigratinib (BGJ398) are small molecule drugs with distinct molecular structures that block FGFR signaling by inhibiting their intracellular tyrosine kinase activities. Erdafitinib was approved for the treatment of locally advanced or metastatic urothelial carcinoma with FGFR2 and FGFR3 alterations (Al‐Obaidy & Cheng, 2021; Bansal et al, 2021; D'Angelo et al, 2020; Hanna, 2019; Loriot et al, 2019; Nauseef et al, 2020; Perera et al, 2017; Roubal et al, 2020). Pemigatinib and Infigratinib were approved for the treatment of unresectable or metastatic cholangiocarcinoma with FGFR2 alterations (Hoy, 2020; Kang, 2021; Rizzo et al, 2021).…”

Section: Development Of Fgf Pathway Inhibitors As Pharmaceuticalsmentioning

confidence: 99%

New developments in the biology of fibroblast growth factors

Ornitz

Itoh

2022

WIREs Mechanisms of Disease

View full text Add to dashboard Cite

The fibroblast growth factor (FGF) family is composed of 18 secreted signaling proteins consisting of canonical FGFs and endocrine FGFs that activate four receptor tyrosine kinases (FGFRs 1-4) and four intracellular proteins (intracellular FGFs or iFGFs) that primarily function to regulate the activity of voltagegated sodium channels and other molecules. The canonical FGFs, endocrine FGFs, and iFGFs have been reviewed extensively by us and others. In this review, we briefly summarize past reviews and then focus on new developments in the FGF field since our last review in 2015. Some of the highlights in the past 6 years include the use of optogenetic tools, viral vectors, and inducible transgenes to experimentally modulate FGF signaling, the clinical use of small molecule FGFR inhibitors, an expanded understanding of endocrine FGF signaling, functions for FGF signaling in stem cell pluripotency and differentiation, roles for FGF signaling in tissue homeostasis and regeneration, a continuing elaboration of mechanisms of FGF signaling in development, and an expanding appreciation of roles for FGF signaling in neuropsychiatric diseases.

show abstract

Section: Development Of Fgf Pathway Inhibitors As Pharmaceuticalsmentioning

confidence: 99%

New developments in the biology of fibroblast growth factors

Ornitz

Itoh

2022

WIREs Mechanisms of Disease

View full text Add to dashboard Cite

show abstract

“…Previous studies have shown an ORR of 40% (95% CI: 31-50% including 3% complete response). However, erdafitinib exhibits ocular toxicity that calls for special attention [218][219][220]. The long-term follow-up of phase II study showed a similar safety profile to the first analysis.…”

Section: Sternberg Et Al In the Randomized Clinical Trial Evaluated I...mentioning

confidence: 75%

Management of Bladder Cancer Patients with Clinical Evidence of Lymph Node Invasion (cN+)

Małkiewicz¹,

Gurwin²,

Karwacki³

et al. 2022

Preprint

View full text Add to dashboard Cite

The purpose of this review is to present the current knowledge about the diagnostic and treatment options in bladder cancer (BCa) patients with clinically positive lymph nodes (cN+). In this review compaction of CT and MRI performance in preoperative prediction of lymph node invasion (LNI) in BCa patients was presented, along with other diagnostic methods. Most scientific societies do not distinguish cN+ patients in their guidelines, recommendations concern muscle-invasive bladder cancer (MIBC) and differ between associations. Currently, the standard treatment of patients with MIBC is radical cystectomy (RC) with bilateral pelvic lymph node dis-section (PLND). The template of PLND and its therapeutic value remain debatable. Moreover, most guidelines recommend neoadjuvant chemotherapy (NAC). However, there is still lack of definitive evidence of the superiority of neoadjuvant chemotherapy over adjuvant chemotherapy. Nevertheless, the curative treatment that provides the best long-term survival in cN+ patients is a multimodal approach with a combination of chemotherapy and RC. Recent studies demonstrate the growing importance of immunotherapy. Special attention should be paid to cN+ BCa patients as the oncological outcomes are significantly worse for this group.

show abstract

“…Previous studies have shown an ORR of 40% (95% CI: 31–50%, including 3% complete response). However, erdafitinib exhibits ocular toxicity that calls for special attention [ 184 , 185 , 186 ]. The long-term follow-up of the phase II study showed a similar safety profile to the first analysis.…”

Section: Treatment Of Cn+ Patientsmentioning

confidence: 99%

Management of Bladder Cancer Patients with Clinical Evidence of Lymph Node Invasion (cN+)

Małkiewicz

Gurwin

Karwacki

et al. 2022

Cancers

View full text Add to dashboard Cite

The purpose of this review is to present the current knowledge about the diagnostic and treatment options for bladder cancer (BCa) patients with clinically positive lymph nodes (cN+). This review shows compaction of CT and MRI performance in preoperative prediction of lymph node invasion (LNI) in BCa patients, along with other diagnostic methods. Most scientific societies do not distinguish cN+ patients in their guidelines; recommendations concern muscle-invasive bladder cancer (MIBC) and differ between associations. The curative treatment that provides the best long-term survival in cN+ patients is a multimodal approach, with a combination of neoadjuvant chemotherapy (NAC) and radical cystectomy (RC) with extended pelvic lymph node dissection (ePLND). The role of adjuvant chemotherapy (AC) remains uncertain; however, emerging evidence indicates comparable outcomes to NAC. Therefore, in cN+ patients who have not received NAC, AC should be implemented. The response to ChT is a crucial prognostic factor for cN+ patients. Recent studies demonstrated the growing importance of immunotherapy, especially in ChT-ineligible patients. Moreover, immunotherapy can be suitable as adjuvant therapy in selected cases. In cN+ patients, the extended template of PLND should be utilized, with the total resected node count being less important than the template. This review is intended to draw special attention to cN+ BCa patients, as the oncological outcomes are significantly worse for this group.

show abstract

An evaluation of the efficacy and safety of erdafitinib for the treatment of bladder cancer

Cited by 8 publications

References 40 publications

New developments in the biology of fibroblast growth factors

New developments in the biology of fibroblast growth factors

Management of Bladder Cancer Patients with Clinical Evidence of Lymph Node Invasion (cN+)

Management of Bladder Cancer Patients with Clinical Evidence of Lymph Node Invasion (cN+)

Contact Info

Product

Resources

About